FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4290793772> ?p ?o ?g. }

• W4290793772 endingPage "378" @default.
• W4290793772 startingPage "374" @default.
• W4290793772 abstract "The aim of this study is to evaluate the outcomes and tolerance of immune checkpoint inhibitors (ICIs) for patients with recurrent chordoma. We reviewed the records of 17 patients with recurrent chordomas who received ICIs for progressing disease as part of their treatment between 2016 and 2020. Response was assessed using response evaluation criteria in solid tumors 1.1 criteria. The Kaplan-Meier method was used to estimate the duration of response, progression-free survival (PFS), and overall survival (OS). Clinical benefit was defined as having stable disease (SD), a partial response, or a complete response. The median follow-up from the start of ICIs was 29 months [interquartile range (IQR): 13-35 m]. The majority received pembrolizumab (n=9, 53%), and the median number of cycles delivered was 8 (IQR: 7-12). The 1-year OS was 87%, and the 1-year PFS was 56% with a median PFS of 14 months (95% CI, 5-17 mo). After ICI initiation, most patients (n=15, 88%) had clinical benefit consisting of a complete response (n=1, 6%), partial response (n=3, 18%), and stable disease (n=11, 65%). Among all responders (n=15), the median duration of response was 12 months. Toxicities were limited: 2 (12%) patients having grade 3/4 immune-related toxicities (colitis, grade 3; myocarditis, grade 4). We observed a high rate of clinical benefit and favorable durability from ICI use for patients with recurrent chordoma. These data provide support for the integration of ICIs as a standard first-line systemic therapy option for patients with recurrent chordoma. Prospective studies are warranted to further evaluate efficacy and enhance response rates." @default.
• W4290793772 created "2022-08-09" @default.
• W4290793772 creator A5002293304 @default.
• W4290793772 creator A5004620963 @default.
• W4290793772 creator A5009191269 @default.
• W4290793772 creator A5014216453 @default.
• W4290793772 creator A5018624284 @default.
• W4290793772 creator A5033776881 @default.
• W4290793772 creator A5033777229 @default.
• W4290793772 creator A5037851639 @default.
• W4290793772 creator A5043710960 @default.
• W4290793772 creator A5051760579 @default.
• W4290793772 creator A5056438282 @default.
• W4290793772 creator A5061333234 @default.
• W4290793772 creator A5071575774 @default.
• W4290793772 creator A5071747925 @default.
• W4290793772 creator A5072907410 @default.
• W4290793772 creator A5074671045 @default.
• W4290793772 creator A5087234749 @default.
• W4290793772 creator A5089849331 @default.
• W4290793772 date "2022-08-04" @default.
• W4290793772 modified "2023-10-17" @default.
• W4290793772 title "Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma" @default.
• W4290793772 cites W1175827129 @default.
• W4290793772 cites W1729209718 @default.
• W4290793772 cites W1970135198 @default.
• W4290793772 cites W1973312390 @default.
• W4290793772 cites W1979378169 @default.
• W4290793772 cites W1988995169 @default.
• W4290793772 cites W2014643917 @default.
• W4290793772 cites W2021657948 @default.
• W4290793772 cites W2039848937 @default.
• W4290793772 cites W2051618897 @default.
• W4290793772 cites W2144717536 @default.
• W4290793772 cites W2215252773 @default.
• W4290793772 cites W2586748258 @default.
• W4290793772 cites W2634549532 @default.
• W4290793772 cites W2765811069 @default.
• W4290793772 cites W2798151915 @default.
• W4290793772 cites W2913113544 @default.
• W4290793772 cites W2982677033 @default.
• W4290793772 cites W3039984729 @default.
• W4290793772 cites W3134900802 @default.
• W4290793772 cites W3167445921 @default.
• W4290793772 cites W4200197506 @default.
• W4290793772 doi "https://doi.org/10.1097/cji.0000000000000431" @default.
• W4290793772 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35943386" @default.
• W4290793772 hasPublicationYear "2022" @default.
• W4290793772 type Work @default.
• W4290793772 citedByCount "5" @default.
• W4290793772 countsByYear W42907937722022 @default.
• W4290793772 countsByYear W42907937722023 @default.
• W4290793772 crossrefType "journal-article" @default.
• W4290793772 hasAuthorship W4290793772A5002293304 @default.
• W4290793772 hasAuthorship W4290793772A5004620963 @default.
• W4290793772 hasAuthorship W4290793772A5009191269 @default.
• W4290793772 hasAuthorship W4290793772A5014216453 @default.
• W4290793772 hasAuthorship W4290793772A5018624284 @default.
• W4290793772 hasAuthorship W4290793772A5033776881 @default.
• W4290793772 hasAuthorship W4290793772A5033777229 @default.
• W4290793772 hasAuthorship W4290793772A5037851639 @default.
• W4290793772 hasAuthorship W4290793772A5043710960 @default.
• W4290793772 hasAuthorship W4290793772A5051760579 @default.
• W4290793772 hasAuthorship W4290793772A5056438282 @default.
• W4290793772 hasAuthorship W4290793772A5061333234 @default.
• W4290793772 hasAuthorship W4290793772A5071575774 @default.
• W4290793772 hasAuthorship W4290793772A5071747925 @default.
• W4290793772 hasAuthorship W4290793772A5072907410 @default.
• W4290793772 hasAuthorship W4290793772A5074671045 @default.
• W4290793772 hasAuthorship W4290793772A5087234749 @default.
• W4290793772 hasAuthorship W4290793772A5089849331 @default.
• W4290793772 hasConcept C119060515 @default.
• W4290793772 hasConcept C121608353 @default.
• W4290793772 hasConcept C126322002 @default.
• W4290793772 hasConcept C141071460 @default.
• W4290793772 hasConcept C143998085 @default.
• W4290793772 hasConcept C2776694085 @default.
• W4290793772 hasConcept C2777701055 @default.
• W4290793772 hasConcept C2778822529 @default.
• W4290793772 hasConcept C2779134260 @default.
• W4290793772 hasConcept C2779984678 @default.
• W4290793772 hasConcept C2780057760 @default.
• W4290793772 hasConcept C2781190729 @default.
• W4290793772 hasConcept C3019096185 @default.
• W4290793772 hasConcept C71924100 @default.
• W4290793772 hasConcept C90924648 @default.
• W4290793772 hasConceptScore W4290793772C119060515 @default.
• W4290793772 hasConceptScore W4290793772C121608353 @default.
• W4290793772 hasConceptScore W4290793772C126322002 @default.
• W4290793772 hasConceptScore W4290793772C141071460 @default.
• W4290793772 hasConceptScore W4290793772C143998085 @default.
• W4290793772 hasConceptScore W4290793772C2776694085 @default.
• W4290793772 hasConceptScore W4290793772C2777701055 @default.
• W4290793772 hasConceptScore W4290793772C2778822529 @default.
• W4290793772 hasConceptScore W4290793772C2779134260 @default.
• W4290793772 hasConceptScore W4290793772C2779984678 @default.
• W4290793772 hasConceptScore W4290793772C2780057760 @default.
• W4290793772 hasConceptScore W4290793772C2781190729 @default.

• next